Immunovia spent 15 years developing a blood test to detect pancreatic cancer early — then its pivotal trial failed in 2022 and the stock lost 80 percent overnight, ending the clinical program that had raised 150 million dollars.
Evaluating only Immunovia’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Market collapse.
Key Events Timeline
FOUNDING
Immunovia founded
LAYOFF
Market downturn forces cuts
SHUTDOWN
Sudden Collapse: Immunovia ceases operations
Full Analysis
Free · no account needed
Documented cause
Immunovia developed IMMray PanCan-d, a blood-based protein biomarker test for early-stage pancreatic cancer detection. The unmet clinical need was enormous — pancreatic cancer is detected late in 80 percent of cases. But the company pivotal study, released in May 2022, failed to show the sensitivity and specificity needed for clinical utility. The stock collapsed 80 percent in a day, the clinical program was suspended, and the company began wind-down procedures.
Lesson
“Cancer diagnostics companies must validate sensitivity and specificity in large real-world populations before pivotal trials — small training cohorts systematically overfit biomarker performance.”